WHAT IS ALREADY KNOWN ON THIS TOPIC
pericarditis, RP
ADVERSE EFFECTS, PERICARDITIS, RECURRENCE, PERICARDITIS
Management of recurrent pericarditis (RP) involves polypharmacy, including long-term glucocorticoid treatment, which is associated with adverse effects. Rapid tapering of glucocorticoids has been associated with increased risk of pericarditis recurrence, and so clinicians often slowly taper oral pericarditis therapies. The phase III trial Rilonacept inHibition of interleukin-1 Alpha and beta for recurrent Pericarditis: a pivotal Symptomatology and Outcomes study (RHAPSODY) demonstrated the efficacy and safety of rilonacept, an IL-1α and IL-1β cytokine trap, for RP.